Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

istockoz Apr. 5 at 3:39 AM

$AKBA I bought at $4.++ and I bought more at $0.27 … and when it was at $4.++ again, I did not consider selling and now at $1.30s I added more!! That’s what buy low looks like when people say “buy low, sell high”. We are yet to see the “high” in that saying! And we will see it!

0 · Reply

Mr_Pithy Apr. 5 at 1:39 AM

$AKBA Simply Wall Street is merely $5.47 shy of $30.00. Good luck ☘️ to all of our honest investors.

0 · Reply

Mr_Pithy Apr. 5 at 1:28 AM

$AKBA Market Beat reveals 4 straight quarters of significantly more institutional buying than selling, including Q4-25 wherein Akebia w/drew its Vafseo NDD NDA from FDA because its proposed trial was going to be too large, time consuming & expensive. Good luck ☘️.

0 · Reply

Mr_Pithy Apr. 5 at 1:00 AM

$AKBA (1)Total inflows & outflows $163.20M ($141.03 + $22.17M). 86.415% inflows. 13.584% outflows. (2)Total buyers & sellers 150. 78% buyers. 22% sellers. Inflow & buyers much greater percentage. Good luck 🍀 to all of us.

0 · Reply

Paperglider Apr. 4 at 10:03 PM

$AKBA Valid observation—choosing "evaluating" over "developing" signals a pivot from operational execution to strategic capital allocation. It effectively asks: "Should we purchase, construct, or partner?" Vickers is tasked with resolving Akebia’s capital and focus constraints by strategically architecting out-licensing and partnership opportunities. He may specifically guide the "out-licensing" of NDD-subgroup rights (Oncology/HIV) to deep-pocketed specialists who can fund the massive VALOR like safety trials. Akebia gets the Upfront Payment (which funds the AKB-097 basket trial) and keeps a Royalty Stream without the clinical risk. Another instance, Akebia lacks the specialized clinical footprint to scale AKB-10108 for ROP alone; such BD dialogues often precursor formal buyout discussions. An acquirer might view AKB-10108 as a multi-billion dollar ophthalmic winner while maintaining secondary interest in renal or oncology branches. Here is one such scenario

0 · Reply

Chamberlain12 Apr. 4 at 7:59 PM

$AKBA @MB76 would say- he buys all the time big opportunity- the manipulator

0 · Reply

dontbuytrash Apr. 4 at 7:48 PM

$AKBA Akebia investors be like… Bought at $4.X: “This is just a pullback.” Bought at $3.X: “Great buying opportunity.” Bought at $2.X: “Undervalued gem.” Bought at $1.50: “Bottom is in.” Bought at $1.20: “This is the real bottom.” Now at $1.30: “Technically… we’re consolidating.” Meanwhile the chart:📉 “I identify as a ski slope.”

0 · Reply

Paperglider Apr. 4 at 3:27 PM

$AKBA Pay close attention to the 'broader' claims in the abstract of '490' patent application for HIF platform outside CKD. I believe the HIF platform is the main 'Akebia' story which needs good IP protection for fair valuation.

0 · Reply

Paperglider Apr. 4 at 3:14 PM

$AKBA AKB-9090 IP - 'PHD Inhibitor Compounds, Compositions, and Uses' 17/906,653 (& 652) have transitioned from "Application" to "Notice of Allowance" status. USPTO are expected to formally issue by late 2026, securing exclusivity through March 2041. 17/906,650 & 18/041,490: Currently Pending. Akebia is actively prosecuting these to capture broader "continuation" claims based on the success of the Phase 1 trial.

0 · Reply

Paperglider Apr. 4 at 2:17 PM

$AKBA Good news! akebia received "notice of allowance" for TIW dosing patent on April 2nd. this almost guarantees patent approval and Akebia should receive a notification sometime in April about the exact date this patent is going to be published. This essentially seals Vafseo monopoly in DD ESRD until 2042. Still, the main item remains the PTE NFD receipt for the composition patent which is a certainty. I am noticing a flurry of activity on the patent side. Looks like they are cleaning up the IP deck - BO?

1 · Reply

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript

Apr 2, 2026, 4:05 PM EDT - 2 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2026, 4:05 PM EDT - 3 days ago

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

Mar 19, 2026, 4:05 PM EDT - 16 days ago

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

Mar 9, 2026, 5:58 PM EDT - 26 days ago

Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 3, 2026, 8:00 AM EST - 4 weeks ago

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

Feb 26, 2026, 11:27 AM EST - 5 weeks ago

Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:00 AM EST - 5 weeks ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

Feb 19, 2026, 8:00 AM EST - 6 weeks ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Feb 13, 2026, 4:57 PM EST - 7 weeks ago

Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 4, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 13, 2026, 1:21 PM EST - 2 months ago

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts

Jan 12, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Jan 6, 2026, 8:00 AM EST - 3 months ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Dec 1, 2025, 7:00 AM EST - 4 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 4 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB

Nov 24, 2025, 8:00 AM EST - 4 months ago

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 11:01 AM EST - 5 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 5 months ago

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 6:30 PM EST - 5 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Nov 4, 2025, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:00 AM EDT - 5 months ago

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

Oct 29, 2025, 2:13 PM EDT - 5 months ago

FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug

Oct 28, 2025, 4:30 PM EDT - 5 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 20, 2025, 8:08 AM EDT - 5 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Sep 5, 2025, 1:34 AM EDT - 7 months ago

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 28, 2025, 8:17 AM EDT - 7 months ago

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Aug 21, 2025, 8:00 AM EDT - 8 months ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 7, 2025, 7:34 PM EDT - 8 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 8 months ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:00 AM EDT - 8 months ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Jul 31, 2025, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 8, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 4, 2025, 8:00 AM EDT - 10 months ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

May 28, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 13, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:44 PM EDT - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 11 months ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 20, 2025, 8:18 AM EDT - 1 year ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP JOYY

Mar 19, 2025, 10:17 PM EDT - 1 year ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 10:21 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

istockoz Apr. 5 at 3:39 AM

0 · Reply

Mr_Pithy Apr. 5 at 1:39 AM

$AKBA Simply Wall Street is merely $5.47 shy of $30.00. Good luck ☘️ to all of our honest investors.

0 · Reply

Mr_Pithy Apr. 5 at 1:28 AM

0 · Reply

Mr_Pithy Apr. 5 at 1:00 AM

0 · Reply

Paperglider Apr. 4 at 10:03 PM

0 · Reply

Chamberlain12 Apr. 4 at 7:59 PM

$AKBA @MB76 would say- he buys all the time big opportunity- the manipulator

0 · Reply

dontbuytrash Apr. 4 at 7:48 PM

0 · Reply

Paperglider Apr. 4 at 3:27 PM

0 · Reply

Paperglider Apr. 4 at 3:14 PM

0 · Reply

Paperglider Apr. 4 at 2:17 PM

1 · Reply

Mr_Pithy Apr. 4 at 1:49 PM

$AKBA GOAL - STANDARD OF CARE IN A BILLION DOLLAR 💵 BUSINESS - “I’ve never been more confident that the data we’re generating supports that managing anemia with a HIF-PHI … is going to be standard of care.” John P. Butler, CEO of Akebia Therapeutics, Inc., February 2026. Good luck 🍀 to all honest investors.

1 · Reply

Mr_Pithy Apr. 4 at 1:43 PM

$AKBA LOOKING GOOD BEFORE Q1 ‘26 BUS./FINAN. REPORT - (1)’25 revenue $236.2M, 49% increase over ‘24 ($160.2M); (2)Dec. 31st cash/equivalents $184.8M. Akebia expects cash from resources/operations to be sufficient to fund plan for AT LEAST 2 years; (3)SIGNIFICANT Vafseo revenue growth in ‘26 thru extended access to therapy at dialysis orgs. (290,000 patients), new patient starts & improved adherence rates (91%); (4)Post-hoc analysis of INNO2VATE data comparing dialysis patients taking Vafseo or darbepoetin alfa for CKD related anemia, showed STATISTICALLY SIGNIFICANT favorable outcomes … all cause mortality, hospitalizations in patients treated w/ Vafseo (7.7% lower hosp. rate, 16% reduction in hosp. days, 15% lower Medicare costs); (5)VOCAL Phase IIIb trial enrolled July ‘25. Data expected Q4 ‘26. VOICE Phase IV trial enrollment completed. Data expected early ‘27; (5)Pipeline advancement - Praliciguat Phase 2 initiated, AKB-097 Phase 2 start 2H ‘26, AKB-9090 Phase 1 start 1H ‘26. ☘️

0 · Reply

mauriz Apr. 4 at 10:02 AM

$AKBA Happy Easter Buona Pasqua

0 · Reply

Paperglider Apr. 4 at 3:44 AM

$AKBA not sure if these are the NDD CKD subgroups (chemotherapy/AIDS) they would still consider pursuing based on 18/500,471 patent abstract

0 · Reply

Akba_BO Apr. 3 at 9:23 PM

$AKBA Absolute ton of pharma M&A so far this year.will be a record IMO given the $300 billion patent cliff by 2030. https://seekingalpha.com/article/4861112?gt=c5c516ab143ed351

1 · Reply

istockoz Apr. 3 at 9:19 PM

$AKBA using 350 million shares authorized (worst case for valuation); $3 Billion @ $8.58 $4 Billion @ $11.44 $5 Billion @ $14.30 $6 Billion @ $17.15 Today I would be OK with $8.58 valuation .... That would require 600M revenue company; I expect Q1 results to point to that direction!!

3 · Reply

Thorthegod Apr. 3 at 8:49 PM

$AKBA market opened or closed, same result!

0 · Reply

Chamberlain12 Apr. 3 at 8:09 PM

$AKBA Problem- absorbes a lot of cash

0 · Reply

albertwillenborg Apr. 3 at 7:29 PM

$BETR $AKBA wishing everyone a happy Easter

2 · Reply

makinggreen1414 Apr. 3 at 7:23 PM

$AKBA This presentation is long-term optimistic but near-term weak: Lots of “potential” and “could” Very little confirmed, near-term revenue expansion Heavy dependence on future clinical success Heavy reliance on future (not current) success Most of the pipeline (AKB-097, AKB-9090, praliciguat) is still early-stage (Phase 1–2) with meaningful data not expected until 2027. → This means years of uncertainty and risk before any real revenue impact. Pipeline risk is very high A large portion of the data shown is preclinical or animal data, which often fails to translate to humans. → Market may discount this heavily. Delayed catalysts Key value-driving events (VOICE, VOCAL, AKB-097 data) are pushed out 1–2+ years. → Not much near-term upside to support valuation. Vafseo execution risk The company is betting heavily on Vafseo becoming standard of care, but that depends on: Adoption growth Real-world outcomes Competition and reimbursement → If growth stalls, the whole story weakens.

3 · Reply

Dipwhits Apr. 3 at 7:04 PM

$AKBA AKBA isn’t broken — it’s just not a fast mover right now. There’s a real business behind it, but the market is still discounting execution and waiting for consistency. Without a near-term catalyst or volume shift, this trades more like a range than a breakout. Good swing candidate, just don’t expect urgency until something changes.

0 · Reply

john1993 Apr. 3 at 6:22 PM

$AKBA we are 3 days since Q1 2026 closed. And we are about 5 weeks away from Q1 announcement and we are about 18 weeks away from Q2 announcement and we are XYZ weeks away form Q3 and I expect $300B by Q4 2026…. I’m Hasinu 😊 I wish he keeps his talk only about facts and stop with the stupid number predictions and math 635225373 x 62535272825 = 100 trillions market cap by Q1 2026 in about only 5 weeks away

2 · Reply

Market Cap	369.67M
Revenue (ttm)	236.20M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	28.20
Profit Margin	-2.27%
Debt to Equity Ratio	1.48

Volume	1,879,400
Avg Vol	3,204,526
Day's Range	N/A - N/A
Shares Out	267.88M
Stochastic %K	50%
Beta	0.37
Analysts	Strong Sell
Price Target	$4.40